Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $AMLX vs $AMRX | Chartloom

Compare

$AMLX vs $AMRX

Amylyx Pharmaceuticals Inc · Amneal Pharmaceuticals Inc

AMLX

Amylyx Pharmaceuticals Inc

AMRX

Amneal Pharmaceuticals Inc

Compare $AMLX vs $AMRX

Comparing Amylyx Pharmaceuticals Inc and Amneal Pharmaceuticals Inc

AMLXAmylyx Pharmaceuticals Inc

AMRXAmneal Pharmaceuticals Inc

AMLXAmylyx Pharmaceuticals Inc

Market cap

$2.99B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-100.0%

YTD performance

135.1%

52W performance

88.3%

FCF yield

-4.2%

AMRXAmneal Pharmaceuticals Inc

Market cap

$6.25B

P/E (TTM)

40.80x

Forward P/E (NTM)

19.08x

Forward P/S (NTM)

1.89x

Rev growth (TTM)

9.3%

YTD performance

54.6%

52W performance

96.3%

FCF yield

-0.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AMLX

AMRX

Detailed metrics comparison

AMLX

Amylyx Pharmaceuticals Inc

AMRX

Amneal Pharmaceuticals Inc

Market Cap

AMLX$2.99B

AMRX$6.25B

Enterprise Value

AMLX$2.94B

AMRX$8.85B

Price

AMLX$26.85

AMRX$19.57

P/E Ratio

AMLXN/A

AMRX40.80x

P/S Ratio

AMLX17.98x

AMRX2.00x

EV/Sales

AMLX17.63x

AMRX2.84x

EV/EBITDA

AMLX87.31x

AMRX13.14x

P/B Ratio

AMLX14.77x

AMRX192.54x

P/FCF Ratio

AMLXN/A

AMRXN/A

EV/FCF

AMLX-23.17x

AMRX-719.11x

PEG Ratio

AMLXN/A

AMRX1.98x

Forward P/E (NTM)

AMLXN/A

AMRX19.08x

Forward P/S (NTM)

AMLXN/A

AMRX1.89x

Revenue (TTM)

AMLX$0

AMRX$3.12B

Revenue Growth (YoY)

AMLX-100.0%

AMRX9.3%

Forward Rev Growth

AMLX195.4%

AMRX9.0%

Gross Margin (TTM)

AMLX82.8%

AMRX39.3%

Operating Margin (TTM)

AMLX0.0%

AMRX14.6%

EBITDA Margin (TTM)

AMLX0.0%

AMRX21.6%

Net Margin (TTM)

AMLX0.0%

AMRX5.0%

FCF Margin (TTM)

AMLXN/A

AMRX-0.4%

Net Income (TTM)

AMLX$-152M

AMRX$157M

FCF (TTM)

AMLX$-127M

AMRX$-12M

EPS (TTM)

AMLX-$1.37

AMRX$0.48

ROE (TTM)

AMLX-5292.0%

AMRX174.6%

ROA (TTM)

AMLX-4853.0%

AMRX4.3%

ROIC (TTM)

AMLX-5292.0%

AMRX2.1%

Cash

AMLX$49M

AMRX$128M

Debt

AMLX$0

AMRX$2.73B

Net Cash/Debt

AMLX$49M

AMRX$-2.60B

Current Ratio (TTM)

AMLX12.12x

AMRX2.20x

Quick Ratio (TTM)

AMLX11.86x

AMRX1.38x

Debt/Equity (TTM)

AMLX0.00x

AMRX82.62x

Debt/Assets (TTM)

AMLX0.0%

AMRX0.0%

Interest Coverage (TTM)

AMLXN/A

AMRXN/A

Net Debt/EBITDA (TTM)

AMLX0.00x

AMRX0.00x

Beta

AMLX-0.10

AMRX1.22

52W Performance

AMLX88.3%

AMRX96.3%

YTD Performance

AMLX135.1%

AMRX54.6%

% from 52W High

AMLX-34.7%

AMRX-7.6%

% from 52W Low

AMLX147.9%

AMRX104.7%

Asset Turnover (TTM)

AMLX0.50x

AMRX0.85x

FCF Yield (TTM)

AMLX-4.2%

AMRX-0.2%

Earnings Yield (TTM)

AMLX-5.1%

AMRX2.5%

Dividend Yield (TTM)

AMLXN/A

AMRXN/A

Rule of 40

AMLX-100.0

AMRX8.9

EV/GP/RG

AMLXN/A

AMRX1.16

Ticker research

View AMLX research View AMRX research

Metric	AMLX Amylyx Pharmaceuticals Inc	AMRX Amneal Pharmaceuticals Inc
Market & Valuation
Market Cap	$2.99B	$6.25B
Enterprise Value	$2.94B	$8.85B
Price	$26.85	$19.57
P/E Ratio	N/A	40.80x
P/S Ratio	17.98x	2.00x
EV/Sales	17.63x	2.84x
EV/EBITDA	87.31x	13.14x
P/B Ratio	14.77x	192.54x
P/FCF Ratio	N/A	N/A
EV/FCF	-23.17x	-719.11x
PEG Ratio	N/A	1.98x
Forward P/E (NTM)	N/A	19.08x
Forward P/S (NTM)	N/A	1.89x
Revenue & Growth
Revenue (TTM)	$0	$3.12B
Revenue Growth (YoY)	-100.0%	9.3%
Forward Rev Growth	195.4%	9.0%
Profitability
Gross Margin (TTM)	82.8%	39.3%
Operating Margin (TTM)	0.0%	14.6%
EBITDA Margin (TTM)	0.0%	21.6%
Net Margin (TTM)	0.0%	5.0%
FCF Margin (TTM)	N/A	-0.4%
Net Income (TTM)	$-152M	$157M
FCF (TTM)	$-127M	$-12M
EPS (TTM)	-$1.37	$0.48
ROE (TTM)	-5292.0%	174.6%
ROA (TTM)	-4853.0%	4.3%
ROIC (TTM)	-5292.0%	2.1%
Financial Health
Cash	$49M	$128M
Debt	$0	$2.73B
Net Cash/Debt	$49M	$-2.60B
Current Ratio (TTM)	12.12x	2.20x
Quick Ratio (TTM)	11.86x	1.38x
Debt/Equity (TTM)	0.00x	82.62x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.10	1.22
52W Performance	88.3%	96.3%
YTD Performance	135.1%	54.6%
% from 52W High	-34.7%	-7.6%
% from 52W Low	147.9%	104.7%
Efficiency & Yields
Asset Turnover (TTM)	0.50x	0.85x
FCF Yield (TTM)	-4.2%	-0.2%
Earnings Yield (TTM)	-5.1%	2.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	8.9
EV/GP/RG	N/A	1.16
Ticker research	View AMLX research	View AMRX research

Valuation

P/E Ratio

AMRX

40.80x

P/S Ratio

AMRX

2.00x

AMLX

17.98x

EV/FCF

AMRX

-719.11x

AMLX

-23.17x

Growth & revenue

Revenue Growth TTM

AMRX

9.3%

AMLX

-100.0%

Forward Revenue Growth

AMLX

195.4%

AMRX

9.0%

Profitability & performance

Gross Margin

AMLX

82.8%

AMRX

39.3%

ROE

AMRX

174.6%

AMLX

-5292.0%

FCF Yield %

AMRX

-0.2%

AMLX

-4.2%

52-Week Performance

AMRX

96.3%

AMLX

88.3%

Detailed metrics comparison

AMLX

Amylyx Pharmaceuticals Inc

AMRX

Amneal Pharmaceuticals Inc

Market Cap

AMLX$2.99B

AMRX$6.25B

Enterprise Value

AMLX$2.94B

AMRX$8.85B

Price

AMLX$26.85

AMRX$19.57

P/E Ratio

AMLXN/A

AMRX40.80x

P/S Ratio

AMLX17.98x

AMRX2.00x

EV/Sales

AMLX17.63x

AMRX2.84x

EV/EBITDA

AMLX87.31x

AMRX13.14x

P/B Ratio

AMLX14.77x

AMRX192.54x

P/FCF Ratio

AMLXN/A

AMRXN/A

EV/FCF

AMLX-23.17x

AMRX-719.11x

PEG Ratio

AMLXN/A

AMRX1.98x

Forward P/E (NTM)

AMLXN/A

AMRX19.08x

Forward P/S (NTM)

AMLXN/A

AMRX1.89x

Revenue (TTM)

AMLX$0

AMRX$3.12B

Revenue Growth (YoY)

AMLX-100.0%

AMRX9.3%

Forward Rev Growth

AMLX195.4%

AMRX9.0%

Gross Margin (TTM)

AMLX82.8%

AMRX39.3%

Operating Margin (TTM)

AMLX0.0%

AMRX14.6%

EBITDA Margin (TTM)

AMLX0.0%

AMRX21.6%

Net Margin (TTM)

AMLX0.0%

AMRX5.0%

FCF Margin (TTM)

AMLXN/A

AMRX-0.4%

Net Income (TTM)

AMLX$-152M

AMRX$157M

FCF (TTM)

AMLX$-127M

AMRX$-12M

EPS (TTM)

AMLX-$1.37

AMRX$0.48

ROE (TTM)

AMLX-5292.0%

AMRX174.6%

ROA (TTM)

AMLX-4853.0%

AMRX4.3%

ROIC (TTM)

AMLX-5292.0%

AMRX2.1%

Cash

AMLX$49M

AMRX$128M

Debt

AMLX$0

AMRX$2.73B

Net Cash/Debt

AMLX$49M

AMRX$-2.60B

Current Ratio (TTM)

AMLX12.12x

AMRX2.20x

Quick Ratio (TTM)

AMLX11.86x

AMRX1.38x

Debt/Equity (TTM)

AMLX0.00x

AMRX82.62x

Debt/Assets (TTM)

AMLX0.0%

AMRX0.0%

Interest Coverage (TTM)

AMLXN/A

AMRXN/A

Net Debt/EBITDA (TTM)

AMLX0.00x

AMRX0.00x

Beta

AMLX-0.10

AMRX1.22

52W Performance

AMLX88.3%

AMRX96.3%

YTD Performance

AMLX135.1%

AMRX54.6%

% from 52W High

AMLX-34.7%

AMRX-7.6%

% from 52W Low

AMLX147.9%

AMRX104.7%

Asset Turnover (TTM)

AMLX0.50x

AMRX0.85x

FCF Yield (TTM)

AMLX-4.2%

AMRX-0.2%

Earnings Yield (TTM)

AMLX-5.1%

AMRX2.5%

Dividend Yield (TTM)

AMLXN/A

AMRXN/A

Rule of 40

AMLX-100.0

AMRX8.9

EV/GP/RG

AMLXN/A

AMRX1.16

Ticker research

View AMLX research View AMRX research

Metric	AMLX Amylyx Pharmaceuticals Inc	AMRX Amneal Pharmaceuticals Inc
Market & Valuation
Market Cap	$2.99B	$6.25B
Enterprise Value	$2.94B	$8.85B
Price	$26.85	$19.57
P/E Ratio	N/A	40.80x
P/S Ratio	17.98x	2.00x
EV/Sales	17.63x	2.84x
EV/EBITDA	87.31x	13.14x
P/B Ratio	14.77x	192.54x
P/FCF Ratio	N/A	N/A
EV/FCF	-23.17x	-719.11x
PEG Ratio	N/A	1.98x
Forward P/E (NTM)	N/A	19.08x
Forward P/S (NTM)	N/A	1.89x
Revenue & Growth
Revenue (TTM)	$0	$3.12B
Revenue Growth (YoY)	-100.0%	9.3%
Forward Rev Growth	195.4%	9.0%
Profitability
Gross Margin (TTM)	82.8%	39.3%
Operating Margin (TTM)	0.0%	14.6%
EBITDA Margin (TTM)	0.0%	21.6%
Net Margin (TTM)	0.0%	5.0%
FCF Margin (TTM)	N/A	-0.4%
Net Income (TTM)	$-152M	$157M
FCF (TTM)	$-127M	$-12M
EPS (TTM)	-$1.37	$0.48
ROE (TTM)	-5292.0%	174.6%
ROA (TTM)	-4853.0%	4.3%
ROIC (TTM)	-5292.0%	2.1%
Financial Health
Cash	$49M	$128M
Debt	$0	$2.73B
Net Cash/Debt	$49M	$-2.60B
Current Ratio (TTM)	12.12x	2.20x
Quick Ratio (TTM)	11.86x	1.38x
Debt/Equity (TTM)	0.00x	82.62x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.10	1.22
52W Performance	88.3%	96.3%
YTD Performance	135.1%	54.6%
% from 52W High	-34.7%	-7.6%
% from 52W Low	147.9%	104.7%
Efficiency & Yields
Asset Turnover (TTM)	0.50x	0.85x
FCF Yield (TTM)	-4.2%	-0.2%
Earnings Yield (TTM)	-5.1%	2.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	8.9
EV/GP/RG	N/A	1.16
Ticker research	View AMLX research	View AMRX research